Tackling NTDs
Introduction of global public-private partnership initiatives
| Participation in "WIPO Re:Search" to Develop Drugs and Vaccines for Tropical Diseases | Since 2011, the World Intellectual Property Organization (WIPO) has sponsored the Global Initiative "WIPO Re:Search", a consortium to develop drugs and vaccines for the treatment of malaria, tuberculosis, NTDs and other infectious diseases. Eisai and Takeda, members of the JPMA have been participating.
Through WIPO Re:Search, both companies have been cooperating in compound screening for medicines at research institutions in various countries including Africa as well as in developing vaccines. |
|---|---|
| Participation in the London Declaration on Neglected Tropical Diseases | In January 2012, Eisai, together with 12 pharmaceutical companies worldwide, announced a joint statement that includes the Bill and Melinda Gates Foundation, the World Health Organization (WHO), the World Bank, the U.S. and British governments and governments from countries that are endemic for NTDs, built the largest global public-private partnership in global health. The partnership announced "London Declaration", to work together to eliminate NTDs 10 diseases by 2020. |
| A Historic Partnership in the Fight Against NTDs | Eisai has endorsed the Kigali Declaration announced at the Kigali Summit on Malaria and Neglected Tropical Diseases (NTDs) on June 23, 2022 in Kigali, the capital of the Republic of Rwanda. The Kigali Declaration, the successor of the London Declaration, is commitment of stakeholders for the elimination of NTDs 2021-2030 by eradicating two NTDs, eliminating at least one NTD in 100 countries and decreasing the number of people requiring interventions for NTDs by 90%. Video shows the partnership of pharmaceutical companies against NTDs. https://www.eisai.com/kigalideclaration/index-2.html  |
Public-Private Partnerships Originating from Japan "Global Health Technology Fund (Global Health Innovative Technology Fund, GHIT Fund)"
In Japan, there is a growing movement to take the initiative in resolving these issues in developing countries through public-private cooperation. In 2013, the Japan-initiated Public-Private Partnership "Global Health Technology Fund (Global Health Innovative Technology Fund, GHIT Fund)" was established as a groundbreaking initiative for private sector companies to take the initiative and become involved as funding partners. The GHIT Fund was established as the world's first fund specializing in global health research and development through joint funding by government, business, and citizens in partnership across sectors. GHIT fund subsidizes Japan-overseas joint R & D projects for commercialization of drugs, vaccines, and diagnostic agents needed by the poorest people in developing countries to overcome the three major infectious diseases and NTDs.
GHIT Participating Companies
The following companies are participating in the GHIT Fund as partners (As of April 2024).
| Full partners | Astellas Pharma Inc., Chugai Pharmaceutical, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Shionogi & Co., Ltd., Takeda Pharmaceutical Company Limited. |
|---|---|
| Associate partners | Fujirebio Inc., Otsuka Pharmaceutical Co., Ltd., Remedy & Company Corporation |
| Affiliate partners | Fujifilm Co., Ltd., Kyowa Kirin Co., Ltd., Merck Ltd., Mitsubishi Tanabe Pharma Corporation and Sumitomo Pharma Co., Ltd. |
The Japan Pharmaceutical Manufacturers Association aims to strengthen Japan's international contribution in the field of global health through the creation of new drugs for infectious diseases in developing countries by leveraging our strengths in new drug development based on advanced science and technology.